r

therapy

NADOLOL: NEW ~-BLOCKER FROM SQUIBB WITH A LONG HALF-LIFE

Shows·effective-use-io hypertension-Nadolol ('Corgaro', Squibb), a new long acting ~-blocker, reduced supine diastolic BP by 10% or more in 22 of 30 documented patients with mild to moderate essential hypertension. 12 ~fthe 22 responders became normotensive. Nadolol dosage in most patients was 20-80mg bid for 14 weeks. Overall, mt'ml BP decreased from 173/109 to 154/ 96mm Hg supine and average heart rate fell ftom 80 to 6 t beats per minute. In the 22 patients with a greater than to % fall, BP dropped from t 68/108 to t 42/90mm Hg. Five of 7 patients who had previously required multiple drug therapy were controlled on nadolol alone. Nine patients in the study experienced side effects other than bradycardia. Bradycardia when present was asymptomatic but caused one patient to withdraw. Of 23 patients who continued for a further t 5 months (median), nadoiol maintained or bettered the original BP response in I 7 cases. Hitzenberaer. G.: Journal of International Medical Research 7: 33 (No I, 1979)

And when given once-a-day for angina Propranolol qid and Dadolol once daily had similar effects on anginal attacks and consumption of glyceryl trinitrilte (nitroglycerin) in 29 anginal patients in a ) 4-week double-blind study but nadolol produced better performance in exercise time. Improvements were maintained and there were no serious side effects or laboratory abnormalities. Prager. G.: Journal of International Medical Research 7: 39 (No I, 1979)

8 INPHARMA 3 Mar 1979 0156-2703/79/0303-0006 $00.50/0 © ADIS Press